FarmaKology Newsletter - Issue #60
PIQUR Therapeutics Founded in 2011 as a spin-off of the University of Basel, Switzerland, PIQUR Therapeutics AG develops breakthrough targeted oncology and dermatology medicines for the treatment of cancers and genetic diseases. PIQUR’s lead compound bimiralisib focuses on the dual inhibition of the PI3K/mTOR pathway. Both PI3K and mTOR are clinically validated drug targets in oncology and dermato-oncology.
Boston Scientific Launches ACURATE neo2™ Aortic Valve System in Europe
Boston Scientific Corporation today announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Europe. This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platform designed with a number of features to improve upon the clinical performance of the original ACURATE neo platform. Compared to the previous generation device, the ACURATE neo2 valve system also has an expanded indication for patients with aortic stenosis – with no specified age or risk level – who are considered appropriate candidates for the therapy by their heart team, including a cardiac surgeon.
BridgeBio Pharma And Affiliate Origin Biosciences Announces FDA Acceptance Of Its New Drug Application For Fosdenopterin For The Treatment Of MoCD Type A
BridgeBio Pharma, Inc. and affiliate Origin Biosciences today announced the US Food and Drug Administration (FDA) has accepted its New Drug Application for fosdenopterin (previously BBP-870/ORGN001), a cyclic pyranopterin monophosphate substrate replacement therapy, for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.
Uqora Develops the First Non-Antibiotic Treatment Option for UTIs
Uqora announces the launch of a new drug development program for the non-antibiotic treatment of urinary tract infection (UTIs) caused by E. coli. Currently, UTIs can only be treated with antibiotics; however antibiotic-resistance continues to rise leaving many patients in a vicious cycle of repeat infections. With this innovation, Uqora continues to expand its holistic and proactive approach to total urinary health care.
Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a strategic supply partnership with the Drugs for Neglected Disease Initiative (DNDi), a collaborative, patients’ needs-driven, non-profit drug research and development organization that is developing new treatments for neglected diseases, for the supply of a CpG oligonucleotide, as part of a combination therapy used in the treatment of cutaneous leishmaniasis infections. This project is supported by the Global Health Innovative Technology (GHIT) Fund.
Research & Study
Vitamin D can help prevent contracting COVID-19
Cannabinoid shows promise as antibiotic for MRSA
Vitamin D-Rich Diet Helps Stave Off Dementia
Stream World Mental Health Day - Sir Norman Lamb by The MedTalk Podcast from desktop or your mobile device